Compare NE & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NE | GKOS |
|---|---|---|
| Founded | 1985 | 1998 |
| Country | United States | United States |
| Employees | 4500 | N/A |
| Industry | Other Specialty Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 9.0B |
| IPO Year | N/A | 2015 |
| Metric | NE | GKOS |
|---|---|---|
| Price | $40.54 | $169.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $46.00 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 1.7M | 843.3K |
| Earning Date | 04-26-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.98% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $507,442,000.00 |
| Revenue This Year | N/A | $23.32 |
| Revenue Next Year | $9.18 | $27.43 |
| P/E Ratio | $32.79 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $26.20 | $73.16 |
| 52 Week High | $54.98 | $184.00 |
| Indicator | NE | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 72.97 |
| Support Level | N/A | $98.22 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 7.09 |
| MACD | 0.00 | 0.97 |
| Stochastic Oscillator | 0.00 | 64.00 |
Noble Corp PLC is an offshore drilling contractor for the oil and gas industry that provides contract drilling services to the international oil and gas industry with its fleet of mobile offshore drilling units. The company focuses on a high-specification fleet of floating and jackup rigs and on deploying its drilling rigs in oil and gas basins around the world. The mobile offshore drilling units comprising the offshore rig fleet operate in international markets for contract drilling services and are often redeployed to different regions due to changing customer demand, which consists mainly of large, integrated, independent, and government-owned or controlled oil and gas companies throughout the world.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.